Therapeutic antibodies against cancer.
Therapeutic antibodies against cancer.
复制标题
DOI：
10.1016/j.hoc.2012.02.013
复制
发表时间：
2012-06
影响因子：
2.4
通讯作者：
Dimitrov, Dimiter S.
中科院分区：
文献类型：
--
作者：
Adler, Mark J.;Dimitrov, Dimiter S.
基于抗体的癌症治疗方法在临床上非常成功，目前对其潜力的认识前所未有；13种单克隆抗体（mab）已在欧盟和美国被批准用于临床使用（mylotarg于2010年退出市场）。其中三种单克隆抗体（贝伐单抗、利妥昔单抗、曲妥珠单抗）在2010年销售额超过50亿美元的蛋白质治疗药物中排名前六。包括双特异性单克隆抗体和多特异性融合蛋白、与小分子药物结合的单克隆抗体和优化药代动力学的单克隆抗体在内的数百种单克隆抗体正在临床试验中。然而，挑战仍然存在，似乎需要对机制有更深入的了解，以克服主要问题，包括对治疗的耐药性、靶向性、生物系统的复杂性和个体差异。
Antibody-based therapeutics against cancer are highly successful in clinic and currently enjoy unprecedented recognition of their potential; 13 monoclonal antibodies (mAbs) have been approved for clinical use in the European Union and in the United States (one, mylotarg, was withdrawn from market in 2010). Three of the mAbs (bevacizumab, rituximab, trastuzumab) are in the top six selling protein therapeutics with sales in 2010 of more than $5 bln each. Hundreds of mAbs including bispecific mAbs and multispecific fusion proteins, mAbs conjugated with small molecule drugs and mAbs with optimized pharmacokinetics are in clinical trials. However, challenges remain and it appears that deeper understanding of mechanisms is needed to overcome major problems including resistance to therapy, access to targets, complexity of biological systems and individual variations.
登录
查看更多内容
影响因子：
3.8
作者：
Cameron, David;Casey, Michelle;Geyer, Charles E.
通讯作者：
Geyer, Charles E.
影响因子：
158.5
作者：
Bonner, JA;Harari, PM;Ang, KK
通讯作者：
Ang, KK
影响因子：
5.8
作者：
Baselga, Jose;Perez, Edith A.;Bell, Richard
通讯作者：
Bell, Richard
影响因子：
45.3
作者：
Burstein, HJ;Harris, LN;Winer, EP
通讯作者：
Winer, EP
影响因子：
45.3
作者：
Allegra, Carmen J.;Jessup, J. Milburn;Schilsky, Richard L.
通讯作者：
Schilsky, Richard L.